Why 861,000 Britons Stuck on NHS Waiting Lists Are Quietly Abandoning the Queue — And the NASA-Derived Biological Discovery That's Making It Possible

I didn't set out to investigate red light therapy. I'm a health correspondent, not a wellness blogger. When I began looking into why NHS waiting lists for orthopaedic treatment had reached 861,000 people in late 2025, I expected to write about underfunding, mismanagement, and political failure. I found all three. What I didn't expect was a pattern — thousands of people, quietly solving their own chronic back pain with a device most GPs have never heard of, manufactured out of a warehouse in Trafford Park, Manchester.

The treatment it replicates costs £16,500 in a Harley Street spinal clinic. According to three months of research and the clinical literature I've reviewed, the underlying mechanism is identical.

This is the story of how that's possible. And why nobody official is telling you about it.

Dr Martin Holloway has worked as a GP in West Yorkshire for 23 years. He agreed to speak on condition of a pseudonym.

The NHS waiting list for Trauma and Orthopaedics — the specialty that handles spinal conditions — sat at 861,000 people in October 2025. The median wait is 14.4 weeks. But the median is a comfortable fiction. At the 92nd percentile — nearly one in ten patients — the wait extends beyond 40 weeks nationally. In Mid and South Essex, the orthopaedic wait is 67 weeks. In Wales, for spinal surgery specifically, it is 93 weeks.

"Ninety-three weeks," Dr Holloway said when I quoted him the Wales figure. "That's nearly two years of absolute agony before a surgeon even picks up a scalpel. I refer patients, they go on the list, and they essentially disappear. Some come back much later — and they don't look like the same people. Not because the NHS fixed them. Usually because they fixed themselves."

The NHS 18-week treatment target — a constitutional right in the UK — has not been met since 2016. At current levels, the waiting list would need to halve before it could reach that target. It is not halving.

The postcode lottery compounds the crisis. A patient in Leeds faces a completely different medical destiny than one in Cardiff. Regional NHS Trust data shows orthopaedic wait times ranging from 57 weeks to 93 weeks, determined solely by geography. One in every eight people on an NHS waiting list is suffering from a musculoskeletal or orthopaedic condition, often involving the spine. They are not in the headlines. They are in their living rooms, navigating a world that has shrunk to the size of their four walls.

The standard GP protocol for back pain has become a national punchline amongst sufferers. The "10-minute appointment limit" — described by patients on forums like Mumsnet and Reddit r/UnitedKingdom as a "ticking clock" that prevents any real conversation — typically ends with a prescription for paracetamol and a printout of generic exercises. Patients report being told to "keep mobile," to "manage expectations," and to accept that some pain is simply something they'll need to "live with."

Meanwhile, private treatment exists — and it works. A single consultation at a Harley Street spinal specialist costs between £250 and £500. Photobiomodulation therapy — the specific treatment at the heart of this investigation — runs to £120 per session in private clinics. A full course of private spinal surgery starts at £15,500 in regional UK facilities and reaches £18,000 in Central London. For most of the 861,000 people on that waiting list, this is not a real option. It is a number to be angry at.

Daniel Marsh is 54 years old. He lives in Sale, just south of Manchester, and spent 26 years working as a biomedical equipment engineer — the person responsible for calibrating and maintaining the clinical devices used in NHS hospitals and private facilities alike. He is not a clinician. But he understands medical hardware in a way that most clinicians don't.

In April 2023, his lower back gave way. Not gradually. All at once.

"I'd had niggles for years," he told me when we met at his workshop in Trafford Park. "But this was different. I woke up one morning and genuinely could not get out of bed. The pain was down my leg. My left foot had gone partially numb. I couldn't reach my feet to put my socks on without a lightning bolt through my lower back."

He saw his GP the next day. He was referred for physiotherapy. The wait: sixteen weeks.

"My daughter's wedding was fourteen weeks away. I thought: I am not watching her walk down that aisle without me, sitting in agony, waiting for an NHS appointment that will arrive too late. I was going to fix this myself — or not at all."

What Daniel found, after weeks of reading clinical literature and ringing former colleagues, was a piece of biology that has been sitting in plain sight.

Your spinal discs — the cushioning pads between each vertebra — have no direct blood supply. They are the largest avascular structure in the human body. Unlike muscle or bone, they cannot draw nutrients directly from the bloodstream. Instead, they rely on a slow, passive process called diffusion, absorbing glucose and oxygen through the cartilage endplates that surround them.

When a disc degenerates, those endplates begin to calcify. The diffusion pathways seal off. The disc cells begin to starve. Lactic acid accumulates. The disc desiccates, thins, and loses its ability to cushion the vertebrae above and below. The pain becomes trapped — not because anything is structurally new, but because the cells have lost the energy to repair themselves.

Think of it like a houseplant moved into a room with no windows. You can water it. You can give it plant food — that's the paracetamol, that's the ibuprofen. But you're not solving the problem. The problem is light. Without light, the plant cannot run the biological process that turns those nutrients into usable energy. It wilts anyway.

Your disc cells are the same plant. And the windowless room is your spine's vascular isolation.

What Daniel found next changed everything. Specific wavelengths of light — 660 nanometres (visible red) and 850 nanometres (near-infrared) — can pass through skin and soft tissue and be absorbed directly by the mitochondria of those starving cells. Daniel came to call this process ‘Photonic Recharging.’ It works through a protein called Cytochrome c Oxidase, the cell’s primary light-sensitive receptor. When it absorbs those wavelengths, it triggers an increase in the mitochondrial membrane potential, which drives greater production of ATP — cellular energy. The disc cells receive what they have been starving for. Without a blood vessel in sight.

This is not fringe science. This research originated at NASA's Marshall Space Flight Center in the early 1990s, initially developed to prevent muscle and bone degeneration in astronauts on long-duration space missions. Published clinical studies have demonstrated that these wavelengths can accelerate deep tissue healing by up to 40%. A study in the NIH database confirmed a strong positive correlation — r=0.89 — between increased mitochondrial membrane potential and ATP synthesis following light exposure of this type.

Daniel rang a colleague working at a private laser clinic in Leeds. He asked what equipment they were using. The specifications matched exactly what he'd been reading. He asked what they charged per session. £120. He did the maths: the same clinical mechanism, available only to those who could afford sixteen sessions at £120 each.

"I thought: this isn't magic. It's physics. And physics doesn't belong exclusively to people with Harley Street budgets."

Think about the last time you stood at the kettle waiting for it to boil. The three minutes that became unbearable. The deep thrumming ache that didn't care you had somewhere to be. That wasn't age. That was cellular starvation — and in eleven months of NHS appointments, nobody had explained it until now.

What followed was, by Daniel's own description, six months of obsessive development.

"My wife thought I'd lost the plot. I had LEDs taped to bits of neoprene. It looked like a prop from a low-budget science fiction film." He laughed. "But I wasn't building it for anyone else. I was thinking: if I don't fix this, I'm watching that wedding from the car park."

He sourced clinical-grade LED chips at the correct wavelengths — 660nm and 850nm — and spent months testing different configurations for LED density, belt coverage, and depth of light penetration into deep lumbar tissue. He wore each prototype himself, tracking pain levels and mobility each morning with the precision of someone who has spent a career measuring clinical outcomes.

By week six: the numbness in his left foot had begun to ease. By week ten: he was sleeping through the night for the first time in months. By week thirteen: Daniel Marsh walked his daughter down the aisle.

"I cried. So did she. Not because of the pain being gone — because for months I had genuinely believed that moment was something I was going to miss. And I didn't miss it."

The morning after the wedding, Daniel woke up in a hotel room in Chester. He swung his legs over the side of the bed. Stood up. Walked to the window. He realised, standing there looking at the car park, that he had not counted the steps. For two years, every morning had been a negotiation. This one wasn't. He made a note in the same notebook he'd been using to track his pain levels for six months. The entry read: 'Normal morning.'

After the wedding, his brother-in-law asked if Daniel could build him one. Then a friend from the reception. Then someone posted about it on a chronic pain support forum and 140 enquiries arrived overnight. He had not been planning a business. He had been planning a recovery.

I brought what Daniel had described to James Whitfield, a consultant physiotherapist with 18 years across NHS and private practice in Bristol, without revealing my source.

"The mechanism he's describing is photobiomodulation," Whitfield confirmed immediately. "The wavelengths — 660nm and 850nm — are precisely the ones with the strongest evidence base for deep tissue penetration and mitochondrial stimulation. That's not fringe therapy. That's mainstream clinical literature. The private clinics using this equipment charge accordingly."

"If someone can access this at a cost that doesn't require a Harley Street budget, that genuinely changes things for a very large number of people who are currently suffering unnecessarily."

I asked why GPs don't discuss this with their patients. His answer was measured but direct. "Because photobiomodulation isn't in the NHS clinical pathway for back pain. That pathway is pharmacological first — paracetamol, NSAIDs — then structural: physiotherapy, imaging, surgery. PBM isn't there because it requires equipment the NHS hasn't budgeted for and a clinical framework that hasn't been updated to include it. It's not a conspiracy. The system simply hasn't caught up. But the gap between what effective treatment costs and what most people can actually access is real. And it is leaving hundreds of thousands of people in pain that they don't have to be in."

Full disclosure: I don't have chronic disc degeneration. But I have had lower back pain — a persistent, dull ache that migrates south after two hours at a desk — for about three years. My GP referred me for physiotherapy. The wait was eleven weeks. The exercises helped marginally. The ache returned.

I asked Daniel if I could trial the device for four weeks and write about it honestly, including if it produced no result whatsoever. He agreed without hesitation.

Day 1: A warmth that isn't heat. Difficult to describe. Not unpleasant. Just present.
Day 4: I'm sitting at my desk for longer before the ache starts. I noted it but drew no conclusions.
Week 2: I realise I haven't thought about my back during a three-hour writing session. I write this in my notebook because it is unusual enough to mark.
Week 4: The ache still visits. But it no longer dictates the day.

I'm not claiming this is a miracle. I'm saying it's physics. And physics, unlike the NHS waiting list, doesn't care about your postcode.

What I can tell you is this: if I had a family member on an NHS waiting list for back pain right now, I would not wait for this article to be published before sending them the link to Daniel's device.

I built the following comparison from publicly available NHS data, private clinic pricing, and published clinical success rate studies. These are not approximations.

When I asked Daniel for access to customer feedback, he sent me 4,200 responses from UK users collected over the past year. The voices within that data were consistent in a way that statistics rarely capture.

After three months of investigating this, the options available to someone with chronic back pain in the UK are, in reality, quite simple.

Think about what morning looks like in twelve weeks. Not guaranteed — nothing is. But for 86% of the 4,200 people who’ve used this, morning looked different. The shuffle was shorter. The socks were easier. The kettle became a kettle again, not a test of endurance.

That’s not a miracle. That’s what happens when the cells responsible for repair finally receive the energy to do it.

Now think about what morning looks like in twelve weeks if you don’t.

Option one: keep waiting. Stay on the NHS list. Hope your trust isn't in an extreme-delay zone. Hope your condition doesn't worsen whilst you wait eighteen months for a system that, by its own published data, has not met its statutory treatment targets since 2016. Hope the "keep mobile" advice is enough. For some people, it is. For the 861,000 currently on that list, the evidence suggests otherwise.

Option two: go private. Pay £250 for the initial consultation. Pay £120 per session for the same photobiomodulation treatment at the heart of this investigation. Pay £1,500 to £2,000 for a full clinical course — if you can afford it, if you can get to the clinic, if you can take the time off work. If you can't, this option simply doesn't exist for you. It is a number to be angry at.

Option three: stop waiting. Try the same NASA-researched mechanism that over 4,200 UK back pain sufferers have already accessed this year — same 660nm and 850nm wavelengths as the Harley Street clinic, same ATP-stimulating photobiomodulation process, same clinical evidence base. At £89.90 — a one-time cost, not £120 per session. Dispatched from Manchester within 24 hours. With a 90-day money-back guarantee if it produces no meaningful improvement.

I can't tell you what to do. I'm a journalist, not a clinician. But I can tell you this: the system isn't going to fix itself. The 18-week target hasn't been met in a decade. The waiting list isn't shrinking. And your back isn't going to wait politely for the NHS to catch up.

I asked Daniel why, given the evident demand, he hadn't taken outside investment to scale production.

"Three investors approached me in the first year. One offered £400,000. I turned them all down," he said. "The moment you take that money, you start making decisions that serve investors rather than customers. You cut component costs to hit margins. You source cheaper LEDs. You end up with something that costs £30 less to produce and is 40% less effective. I've watched it happen with medical equipment my entire career. The moment profit becomes the primary driver, the product stops being what it was."

His Trafford Park facility produces a maximum of 300 units per month. Current demand consistently outpaces production. Each batch typically sells through within three to five weeks of arriving in the warehouse. He has one rule he considers non-negotiable: no pre-orders.

"I know what it feels like to be in pain and waiting. I won't take someone's money and then make them wait another fortnight while I catch up with the production run. Either I have stock to ship within 48 hours — or I don't sell. That's the rule."